New eye injection shows promise for diabetic retinopathy
NCT ID NCT07526857
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether faricimab injections can help people with diabetic retinopathy, a diabetes-related eye disease. Over 12 months, 60 patients received the treatment and doctors measured changes in the back of the eye. The goal was to see if the drug could reduce abnormal cells and restore protective pigments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
60 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population includes adult patients,, diagnosed with diabetic macular edema in diabetic retinopathy, treated with eylea 2 or faricimab
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * diagnosis of diabetic macular edema, diabetic retinopathy Exclusion Criteria: * previous ocular surgery, history of vitreoretinal and/or retinal vascular diseases, uveitis, myopia over 6 dioptres, significant corneal and/or lens opacity, glaucoma, ocular MNV related to other causes than nAMD, geographic atrophy, subretinal fibrosis, previous treatments for MNV
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diabetic macular edema are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Naples, Federico II, Napoli, Napoli
Naples, Napoli, 80127, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- The 20-Minute squeeze: how eye injections push pressure up
- Could years of eye injections weigh down the upper eyelid?
- Eye implant takes aim at diabetic macular edema
- Can a single gene therapy injection ease diabetic macular edema?
- Can a new eye injection preserve vision in south asians with diabetes?
- Can a One-Time gene therapy offer lasting protection for diabetic retinopathy?